Grant: Collaborative Research and Development Grants
McMaster University
$104,667.00
Development of diagnostic teststrips incorporating concatameric aptamers for quantitative detection of C. difficile
FY 2014-15
Summary
The emergence of new pathogenic species and strains that are resistant to traditional treatments are amongst the most pressing health concerns of our time. The bird flu virus epidemic and the outbreak of Clostridium difficile in several hospitals across Canada in the past year are the latest examples to drive this point home. These outbreaks can be a huge economic burden and, more importantly, pose a tremendous risk to human health. Early and accurate detection and identification of dangerous pathogens is a crucial step in preventing large-scale outbreaks. This is particularly relevant today as globalization of commerce and decreased travel times have significantly increased the rate and breadth of the spread of infectious agents. Traditional microbial pathogen detection techniques using molecular methods (DNA detection with PCR) or immunological methods require large pathogen concentrations and/or long analysis times - time that can be very precious when assessing a patient with a deteriorating condition or when trying to identify and control a large-scale outbreak. In addition, current methods often cannot distinguish between carriers of a disease and those who are infective (a particular issue with C. difficile). Hence there is still a significant need to develop rapid, sensitive, accurate and inexpensive methods and devices for the detection of pathogens. Equally important is the need for a reliable method that can be put in place quickly to create new sensors and assays to respond to unanticipated outbreaks. The goal of this CRD project is to develop a platform based on nucleic acid aptamers and enzymes that can provide high amplification of a selective binding event between the nucleic acid and the pathogen to allow detection of very low levels of pathogens in minutes on a simple paper-based test strip. The proposal brings together two co-applicants with expertise in DNA aptamer and DNA enzyme technology, biomolecule immobilization and biosensors, and development of bioactive paper-based diagnostics. This team will develop and validate new aptamer and aptazyme sensing platforms for detection of pathogens that can be licensed by our Canadian partner for eventual commercialization.
Program
Collaborative Research and Development Grants
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
435538-2012
Name nom
Brennan, John
Department département
Chemistry & Chemical Biology
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2014
Competition year année de concours
2012
Award amount
104667
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
515
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Instrumentation technology
Area of application fr
Technologie de l'instrumentation
Research subject code
3505
Research subject group en
Analytical chemistry
Research subject group fr
Chimie analytique
Research subject en
Analytical spectroscopy
Research subject fr
Spectroscopie analytique
Partie
2
Nb partie
3
Application title
Development of diagnostic teststrips incorporating concatameric aptamers for quantitative detection of C. difficile
Keyword
NSERC
Application summary
The emergence of new pathogenic species and strains that are resistant to traditional treatments are amongst the most pressing health concerns of our time. The bird flu virus epidemic and the outbreak of Clostridium difficile in several hospitals across Canada in the past year are the latest examples to drive this point home. These outbreaks can be a huge economic burden and, more importantly, pose a tremendous risk to human health. Early and accurate detection and identification of dangerous pathogens is a crucial step in preventing large-scale outbreaks. This is particularly relevant today as globalization of commerce and decreased travel times have significantly increased the rate and breadth of the spread of infectious agents. Traditional microbial pathogen detection techniques using molecular methods (DNA detection with PCR) or immunological methods require large pathogen concentrations and/or long analysis times - time that can be very precious when assessing a patient with a deteriorating condition or when trying to identify and control a large-scale outbreak. In addition, current methods often cannot distinguish between carriers of a disease and those who are infective (a particular issue with C. difficile). Hence there is still a significant need to develop rapid, sensitive, accurate and inexpensive methods and devices for the detection of pathogens. Equally important is the need for a reliable method that can be put in place quickly to create new sensors and assays to respond to unanticipated outbreaks. The goal of this CRD project is to develop a platform based on nucleic acid aptamers and enzymes that can provide high amplification of a selective binding event between the nucleic acid and the pathogen to allow detection of very low levels of pathogens in minutes on a simple paper-based test strip. The proposal brings together two co-applicants with expertise in DNA aptamer and DNA enzyme technology, biomolecule immobilization and biosensors, and development of bioactive paper-based diagnostics. This team will develop and validate new aptamer and aptazyme sensing platforms for detection of pathogens that can be licensed by our Canadian partner for eventual commercialization.